Dr.RENUKA MAHEY, R19438
Assessment of quality of life is being increasingly recognized as a critical measure for evaluating the effectiveness of treatment of glaucoma. Use of BAK preserved anti-glaucoma drugs is associated with ocular surface disease and has the propensity to worsen QoL.
Material and methodology: A total of 110 subjects were divided into three groups; the first group comprising of 40 POAG patients receiving BAK preserved prostaglandins, the second group included 40 POAG patients receiving BAK free travoprost and a third group of 30 age matched controls. All the patients were assessed by a single interviewer with orally administered Quality of Life (GQL-15) and Ocular surface disease index (OSDI) questionnaires.
Conclusion: QoL assessed using the GQL 15 questionnaire was found to be significantly better in patients receiving polyquad preserved drugs as compared to BAK preserved drugs.
PRESENTATION NOT RECEIVED FROM THE AUTHOR.
Leave a Comment